Applications of 5'-O-Dimethoxytrityl-N-Isobutyryl-Deoxyguanosine in Industrial Manufacturing

5'-O-Dimethoxytrityl-N-Isobutyryl-Deoxyguanosine serves as a key nucleoside phosphoramidite derivative, widely employed in controlled, high-yield oligonucleotide synthesis. Our manufacturing focus ensures rigorous quality standards, reliable batch consistency, and full traceability to support demanding downstream industries. The following industrial application scenarios demonstrate its distinctly differentiated roles based on end-use formulations, compliance expectations, processing steps, and final product formats as directly integrated in commercial manufacturing environments.

1. Custom DNA Oligonucleotide Synthesis for Genomic Research

This raw material is a primary monomer unit utilized in automated solid-phase DNA synthesis, supporting the construction of custom oligonucleotide chains required for DNA sequencing, hybridization probes, and molecular diagnostics. Process fit and purity standards are critical in ensuring error-free sequence assembly and downstream biological function.

Industry compliance standards

• ISO 13485 for medical laboratory reagents
• US Pharmacopeia (USP) Nucleic Acid Sequence-based Technology guidelines
• European Pharmacopoeia 10.0 (Ph. Eur.) for oligonucleotides
• ICH Q7 GMP for APIs used in clinical research products

Typical usage ratio

• Ranges from 0.8 to 1.2 molar equivalents per elongation cycle; precise amount set by oligo length and yield targets.

Downstream process integration

• Integrated as the guanosine phosphoramidite during automated DNA chain assembly in solid-phase synthesizers, after which DMT removal and coupling reactions cycle sequentially for full-length oligonucleotide build-up.

Final product types

• Custom DNA primers and probes for PCR/qPCR assays
• Microarray chips and genomic sequencing libraries
• Fluorescent-labeled hybridization probes

2. GMP-Grade Oligonucleotide Therapeutics Manufacturing

This intermediate is employed in the manufacture of therapeutic-grade oligonucleotides, including antisense oligos, aptamers, and siRNA precursors, where material traceability, pyrogen control, and impurity profiles must align with drug substance standards set by regulatory authorities.

Industry compliance standards

• US FDA 21 CFR Part 210/211 for drug substances
• ICH Q3A/Q3B for impurities in new drug substances and products
• EU GMP Part II (ICH Q7)
• Ph. Eur. 10.0 Monograph “Oligonucleotide Drug Substances”

Typical usage ratio

• 0.95–1.05 molar equivalents per cycle; adjusted based on delivery system loading and desired process throughput.

Downstream process integration

• Dispensed directly into GMP-controlled automated synthesizers at the coupling stage, followed by deprotection, HPLC purification, and desalting steps conforming to validated batch records.

Final product types

• Antisense oligonucleotide APIs
• RNAi double-stranded oligonucleotide intermediates
• Therapeutic aptamers

3. Diagnostic Kit and Reagent Manufacturing

Our material underpins the high-throughput synthesis of molecular probes included in commercial nucleic acid diagnostic test kits and research reagent panels. Lot-release standards and batch homogeneity are crucial for end-users who rely on reproducible hybridization performance and specific sequence fidelity in clinical and laboratory settings.

Industry compliance standards

• ISO 13485/ISO 9001 for in vitro diagnostic reagent production
• CLSI EP25-A for reagent lot-release reliability
• US FDA 21 CFR 820 (Quality System Regulation) for diagnostic devices

Typical usage ratio

• 1.0 molar equivalent per phosphoramidite cycle for standard primer/probe synthesis; adjustable for ultra-long DNA constructs.

Downstream process integration

• Charged into phosphoramidite dispensing modules during batchwise or parallel oligonucleotide production, after which reagents undergo QA release, formulation with buffer stabilizers, then integration into diagnostic kit components.

Final product types

• PCR/qPCR diagnostic panels
• Pathogen detection probe kits
• Genotyping and mutation detection kits

4. Commercial-Scale Nucleic Acid Labeling Reagent Production

This intermediate is used for the large-scale preparation of nucleic acid labeling reagents and linkers, crucial for creating site-specific covalent labels (such as fluorophores or biotin) in DNA and RNA modifications. Chemical stability and protection group integrity directly affect final labeling yields and product stability.

Industry compliance standards

• REACH registration for downstream commercial labeling reagents
• ISO 9001:2015 for quality management in reagent manufacturing
• USP Molecular Biology Reagents standards

Typical usage ratio

• Usage typically set at 0.9–1.1 equivalents per nucleotide addition, with exact loading guided by desired label-to-oligo ratio and downstream conjugation efficiency.

Downstream process integration

• Dosed during standard phosphoramidite DNA/RNA chain assembly on solid support, with post-synthesis chemical activation steps for label conjugation, including selective DMT removal for targeted modification sites.

Final product types

• 5’-fluorescently labeled oligonucleotides
• Biotinylated and affinity-tag oligos
• DNA hybridization and FISH reagent probes

5. High-Purity Gene Synthesis Services

This building block is a critical input in contract gene synthesis operations, allowing precise sequence assembly for use in recombinant protein expression, synthetic biology, and CRISPR guide RNA production. Gene synthesis relies on stringent impurity and coupling efficiency profiles to control sequence accuracy and downstream functionality.

Industry compliance standards

• ISO 9001 for contract manufacturing
• Ph. Eur. 10.0 oligonucleotide guidelines when used for clinical trial supply
• US NIH Guidelines for DNA constructs in synthetic biology

Typical usage ratio

• 1.0 molar equivalent per nucleotide position; adjusted for very long constructs or high-GC content sequences to optimize coupling rates and synthesis cycle time.

Downstream process integration

• Added as the guanosine monomer during large-scale DNA assembly on automated gene synthesizers, with subsequent pooling, enzymatic error correction, and plasmid construct assembly.

Final product types

• Synthetic gene fragments
• CRISPR guide RNA templates
• Plasmid DNA for expression systems

6. Reference Standard and Analytical Oligonucleotide Manufacturing

Our production grades support the synthesis of high-purity, well-characterized oligonucleotides serving as analytical reference standards in pharmaceutical quality control labs, ensuring traceability and method validation for nucleic acid assays and bioanalytical methods.

Industry compliance standards

• US Pharmacopeia (USP) Reference Standard quality
• ICH Q6A Specifications for test materials
• ISO 17034:2016 Reference Material Producer guidelines

Typical usage ratio

• Precisely 1.0 equivalent per base addition; strict stoichiometry enables batch-to-batch reproducibility for reference standard documentation.

Downstream process integration

• Administered during custom oligo synthesis runs verified by HPLC, MS, and NMR for traceable analytical reference standards used in release and stability testing.

Final product types

• Oligonucleotide reference standards for QC/QA operations
• Traceable calibrators for bioanalytical method validation
• Analytical spike-in reagents for nucleic acid quantification